Das Ampullenkarzinom – prognostische und therapeutische Unterschiede zum duktalen Adenokarzinom des Pankreas

Zusammenfassung

Das Ampullenkarzinom stellt eine seltene, jedoch in seiner Inzidenz steigende Entität gastrointestinaler Tumoren dar. Aufgrund der anatomischen Lokalisation führt es vergleichsweise früh im Erkrankungsprozess zu einer biliären Gangobstruktion, wodurch eine schnellere Diagnosestellung erleichtert und eine bessere Prognose bedingt werden. Adenome der Ampulla hepatopancreatica und der Papilla duodeni major stellen Vorläuferläsionen des Ampullenkarzinoms dar und besitzen ein 30–40%iges Risiko zur malignen Transformation. Diese Entartungstendenz begründet die Notwendigkeit zur vollständigen/kompletten Abtragung im Rahmen der endoskopischen Therapie. Der Erfolg der endoskopischen Papillektomie wird durch eine Ausdehnung des Befundes in den Pankreashauptgang oder Ductus choledochus erschwert. Endoskopisch nicht sanierbare Adenome und Ampullenkarzinome stellen Indikationen für chirurgische Therapieverfahren dar. Grundsätzlich sollte für benigne Befunde die transduodenale Papillenresektion bervorzugt werden, für maligne Befunde stellt die Pankreaskopfresektion mit systematischer Lymphadenektomie und Level-II-Dissektion des Mesopankreas die onkologisch korrekte Operation dar. Prognostische Faktoren beim Ampullenkarzinom sind: der pankreatobiliäre Subtyp, eine Lymphknoteninfiltration und eine Perineuralscheideninvasion. Die Differenzierung in histopathologische Subtypen gewinnt zunehmend in der Indikationsstellung zur Systemtherapie an Bedeutung. Der Einsatz der neoadjuvanten und adjuvanten Therapie für das Ampullenkarzinom konnte bisher nicht klar definiert werden. Jedoch scheinen Patienten mit dem pankreatobiliären Subtyp oder anderen prognoselimitierenden Faktoren von einer adjuvanten Therapie zu profitieren. Zukünftige Studien werden zur zielgerichteten Therapiefestlegung benötigt.

Abstract

Ampullary carcinoma belongs to the cluster of periampullary cancers and is a rare, but increasing form of gastrointestinal malignancy. Due to the location of the tumour, occurrence of biliary obstruction is common. Symptoms due to the compression of the biliary tract facilitate early diagnosis, evoking a better prognosis. Adenomas of the ampulla of Vater and major duodenal papilla are precursor lesions and possess a risk of 30–40% to progress into a malignancy. Therefore, en-bloc resection is warranted for all ampullary adenomas. Endoscopic papillectomy is aggravated by extension into the pancreatic duct or common bile duct. Surgical resection is indicated whenever endoscopic resection is incomplete or infiltrative growth is suspected. Transduodenal ampullectomy is an alternative to extensive oncological resection in the absence of malignancy. Pancreatoduodenectomy (or Whipple procedure) with systemic lymphadenectomy and mesopancreas excision is the standard procedure of all ampullary carcinomas and incompletely excised adenomas by minimally invasive procedures. The indication for extensive surgical resection includes suspicion of infiltration in endoscopic ultrasound or evidence of malignancy in frozen section during transduodenal ampullectomy. Negative prognostic indicators are implicated by the pancreatobiliary subtype, lymph node metastases and perineural invasion. Differentiation of the different histopathological subtypes thereby increases in clinical relevance. Evidence based guidelines for the clinical practice of neoadjuvant and adjuvant treatment for ampullary carcinoma have yet to be defined. According to the literature available, patients with the pancreatobiliary subtyp or association with other negative prognostic factors seem to benefit from systemic therapy. Further studies are warranted.

Schlüsselwörter

Ampullenkarzinom - Subtypen - onkologische Resektion - multimodale Therapie

Keywords

ampullary carcinoma - subtypes - oncological resection - multimodal therapy

Publication History

Received: 20 January 2022

Accepted after revision: 16 February 2022

Article published online:
04 April 2022

• Literatur

• 1 Zheng-Pywell R, Reddy S. Ampullary Cancer. Surg Clin North Am 2019; 99: 357-367
• 2 Zimmermann C, Wolk S, Aust DE. et al. The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep 2019; 9: 12676
• 3 Avisse C, Flament JB, Delattre JF. Ampulla of Vater. Anatomic, embryologic, and surgical aspects. Surg Clin North Am 2000; 80: 201-212
• 4 Kimura W, Futakawa N, Yamagata S. et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn J Cancer Res 1994; 85: 161-166
• 5 Nagtegaal ID, Odze RD, Klimstra D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020; 76: 182-188
• 6 Schneider M, Büchler MW. Periampullary carcinoma. Chirurg 2021; 92: 769-770
• 7 Lee-Six H, Olafsson S, Ellis P. et al. The landscape of somatic mutation in normal colorectal epithelial cells. Nature 2019; 574: 532-537
• 8 Saha SK, Zhu AX, Fuchs CS. et al. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist 2016; 21: 594-599
• 9 Luchini C, Veronese N, Nottegar A. et al. Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. Pancreas 2019; 48: 70-76
• 10 Kohler I, Jacob D, Budzies J. et al. Phenotypic and genotypic characterization of carcinomas of the papilla of Vater has prognostic and putative therapeutic implications. Am J Clin Pathol 2011; 135: 202-211
• 11 Ehehalt F, Rümmele P, Kersting S. et al. Hepatocyte nuclear factor (HNF) 4α expression distinguishes ampullary cancer subtypes and prognosis after resection. Ann Surg 2011; 254: 302-310
• 12 Kim WS, Choi DW, Choi SH. et al. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol 2012; 105: 266-272
• 13 Ang DC, Shia J, Tang LH. et al. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater. Am J Surg Pathol 2014; 38: 1371-1379
• 14 Asano E, Okano K, Oshima M. et al. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma. J Surg Oncol 2016; 114: 119-127
• 15 Pea A, Riva G, Bernasconi R. et al. Ampulla of Vater carcinoma: Molecular landscape and clinical implications. World J Gastrointest Oncol 2018; 10: 370-380
• 16 Carter JT, Grenert JP, Rubenstein L. et al. Tumors of the ampulla of vater: histopathologic classification and predictors of survival. J Am Coll Surg 2008; 207: 210-218
• 17 Roh YH, Kim YH, Lee HW. et al. The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. Hepatogastroenterology 2007; 54: 1641-1644
• 18 Bronsert P, Kohler I, Werner M. et al. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin. BMC Cancer 2013; 13: 428
• 19 Okano K, Oshima M, Yachida S. et al. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma. J Surg Oncol 2014; 110: 156-162
• 20 Yachida S, Wood LD, Suzuki M. et al. Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell 2016; 29: 229-240
• 21 Gingras MC, Covington KR, Chang DK. et al. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep 2016; 14: 907-919
• 22 Mafficini A, Amato E, Cataldo I. et al. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. Ann Surg 2018; 267: 149-156
• 23 Perrone G, Santini D, Zagami M. et al. COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters. Virchows Arch 2006; 449: 334-340
• 24 Bakkevold KE, Kambestad B. Staging of carcinoma of the pancreas and ampulla of Vater. Tumor (T), lymph node (N), and distant metastasis (M) as prognostic factors. Int J Pancreatol 1995; 17: 249-259
• 25 Asbun HJ, Conlon K, Fernandez-Cruz L. et al. When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. Surgery 2014; 155: 887-892
• 26 Liu XF, Tang K, Sun FB. et al. Partial Resection of the Pancreatic Head and Duodenum for Management of Carcinoma of the Ampulla of Vater: A Case Report. Anticancer Res 2016; 36: 1319-1324
• 27 Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol 2018; 25: 845-847
• 28 Kim SJ, An S, Kang HJ. et al. Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. Surgery 2018; 163: 1071-1079
• 29 Murphy JE, Wo JY, Ryan DP. et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2018; 4: 963-969
• 30 Mokdad AA, Minter RM, Zhu H. et al. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. J Clin Oncol 2017; 35: 515-522
• 31 Tzeng CW, Tran Cao HS, Lee JE. et al. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg 2014; 18: 16-24
• 32 Guo M, Beal EW, Miller ED. et al. Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB. J Surg Oncol 2021; 123: 1558-1567
• 33 Cloyd JM, Wang H, Overman M. et al. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol 2017; 24: 2031-2039
• 34 Oehme F, Hempel S, Pecqueux M. et al. Short-term preoperative drainage is associated with improved postoperative outcomes compared to that of long-term biliary drainage in pancreatic surgery. Langenbecks Arch Surg 2021;
• 35 Müssle B, Hempel S, Kahlert C. et al. Prognostic Impact of Bacterobilia on Morbidity and Postoperative Management After Pancreatoduodenectomy: A Systematic Review and Meta-analysis. World J Surg 2018; 42: 2951-2962
• 36 Stolte M, Pscherer C. Adenoma-carcinoma sequence in the papilla of Vater. Scand J Gastroenterol 1996; 31: 376-382
• 37 Vanbiervliet G, Strijker M, Arvanitakis M. et al. Endoscopic management of ampullary tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021; 53: 429-448
• 38 Distler M, Grützmann R. Transduodenal resection of ampullary tumors. Zentralbl Chir 2012; 137: 319-321
• 39 Schneider L, Contin P, Fritz S. et al. Surgical ampullectomy: an underestimated operation in the era of endoscopy. HPB (Oxford) 2016; 18: 65-71
• 40 Nappo G, Gentile D, Galvanin J. et al. Trans-duodenal ampullectomy for ampullary neoplasms: early and long-term outcomes in 36 consecutive patients. Surg Endosc 2020; 34: 4358-4368
• 41 van der Gaag NA, Rauws EA, van Eijck CH. et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362: 129-137
• 42 Son JH, Kim J, Lee SH. et al. The optimal duration of preoperative biliary drainage for periampullary tumors that cause severe obstructive jaundice. Am J Surg 2013; 206: 40-46
• 43 Yeh CC, Jeng YM, Ho CM. et al. Survival after pancreaticoduodenectomy for ampullary cancer is not affected by age. World J Surg 2010; 34: 2945-2952
• 44 Chen K, Pan Y, Liu XL. et al. Minimally invasive pancreaticoduodenectomy for periampullary disease: a comprehensive review of literature and meta-analysis of outcomes compared with open surgery. BMC Gastroenterol 2017; 17: 120
• 45 Callery MP, Pratt WB, Kent TS. et al. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatoduodenectomy. J Am Coll Surg 2013; 216: 1-14
• 46 Mungroop TH, van Rijssen LB, van Klaveren D. et al. Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS): Design and International External Validation. Ann Surg 2019; 269: 937-943
• 47 Quero G, Fiorillo C, De Sio D. et al. The role of mesopancreas excision for ampullary carcinomas: a single center propensity-score matched analysis. HPB (Oxford) 2021; 23: 1557-1564
• 48 Tol JA, Gouma DJ, Bassi C. et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014; 156: 591-600
• 49 Tol JA, Gouma DJ, Bassi C. et al. Pancreatoduodenectomy With Systematic Mesopancreas Dissection Using a Supracolic Anterior Artery-first Approach. Ann Surg 2015; 262: 1092-1101
• 50 Partelli S, Crippa S, Capelli P. et al. Adequacy of lymph node retrieval for ampullary cancer and its association with improved staging and survival. World J Surg 2013; 37: 1397-1404
• 51 Michalski CW, Liu B, Heckler M. et al. Underutilization of Surgery in Periampullary Cancer Treatment. J Gastrointest Surg 2019; 23: 959-965
• 52 Ecker BL, Vollmer Jr CM, Behrman SW. et al. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma. JAMA Surg 2019; 154: 706-714
• 53 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011-1024
• 54 Bolm L, Ohrner K, Nappo G. et al. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy – A multicenter cohort study. Pancreatology 2020; 20: 433-441
• 55 Vo NP, Nguyen HS, Loh EW. et al. Efficacy and safety of adjuvant therapy after curative surgery for ampullary carcinoma: A systematic review and meta-analysis. Surgery 2021; 170: 1205-1214
• 56 Kang J, Lee W, Shin J. et al. Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis. Langenbecks Arch Surg 2022;
• 57 Moekotte AL, Malleo G, van Roessel S. et al. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. Br J Surg 2020; 107: 1171-1182
• 58 Acharya A, Markar SR, Sodergren MH. et al. Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma. Br J Surg 2017; 104: 814-822